Bharat Parenterals (BPLPHARMA) | Financial Analysis & Statements
Bharat Parenterals Ltd. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
1.2B
Gross Profit
471.5M
40.65%
Operating Income
51.8M
4.47%
Net Income
-8.7M
-0.75%
EPS (Diluted)
₹-1.27
Balance Sheet Metrics
Total Assets
6.5B
Total Liabilities
3.1B
Shareholders Equity
3.4B
Debt to Equity
0.91
Cash Flow Metrics
Revenue & Profitability Trend
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Bharat Parenterals Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 3.4B | 2.6B | 2.2B | 2.1B | 2.0B |
| Cost of Goods Sold | 2.1B | 1.7B | 1.5B | 1.4B | 1.4B |
| Gross Profit | 1.2B | 888.0M | 719.9M | 759.5M | 653.2M |
| Gross Margin % | 36.9% | 34.5% | 33.1% | 35.8% | 32.0% |
| Operating Expenses | |||||
| Research & Development | 65.1M | 10.3M | 10.5M | 10.0M | 9.6M |
| Selling, General & Administrative | 334.1M | 238.7M | 211.8M | 105.1M | 95.5M |
| Other Operating Expenses | 352.3M | 172.8M | 119.0M | 328.5M | 122.7M |
| Total Operating Expenses | 751.6M | 421.8M | 341.2M | 443.6M | 227.8M |
| Operating Income | -308.9M | 171.8M | 157.3M | 210.7M | 282.4M |
| Operating Margin % | -9.2% | 6.7% | 7.2% | 9.9% | 13.8% |
| Non-Operating Items | |||||
| Interest Income | 38.0M | 4.2M | 3.4M | 16.8M | 3.5M |
| Interest Expense | 119.2M | 32.2M | 21.9M | 9.7M | 3.9M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | -339.5M | 187.2M | 235.5M | 278.8M | 271.2M |
| Income Tax | 97.2M | 82.1M | 78.3M | 70.6M | 68.1M |
| Effective Tax Rate % | 0.0% | 43.8% | 33.3% | 25.3% | 25.1% |
| Net Income | -436.8M | 105.1M | 157.1M | 208.2M | 203.2M |
| Net Margin % | -13.0% | 4.1% | 7.2% | 9.8% | 9.9% |
| Key Metrics | |||||
| EBITDA | 142.5M | 312.4M | 311.8M | 355.1M | 357.1M |
| EPS (Basic) | ₹-66.64 | ₹24.94 | ₹28.40 | ₹36.67 | ₹35.59 |
| EPS (Diluted) | ₹-66.64 | ₹24.94 | ₹28.40 | ₹36.67 | ₹35.59 |
| Basic Shares Outstanding | 6554000 | 5821633 | 5774666 | 5740387 | 5729666 |
| Diluted Shares Outstanding | 6554000 | 5821633 | 5774666 | 5740387 | 5729666 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Bharat Parenterals Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 5.6M | 87.1M | 78.5M | 34.0M | 16.8M |
| Short-term Investments | 49.8M | 21.7M | 10.8M | 370.2M | 428.1M |
| Accounts Receivable | 1.7B | 1.4B | 1.1B | 734.0M | 678.3M |
| Inventory | 719.5M | 614.7M | 378.4M | 207.6M | 224.3M |
| Other Current Assets | 437.3M | 405.7M | 202.2M | 90.2M | 1.0M |
| Total Current Assets | 3.6B | 2.6B | 1.8B | 1.4B | 1.5B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 60.2M | 48.5M | 56.6M | 397.5M | 56.0M |
| Goodwill | 1.1B | 10.4M | 0 | - | - |
| Intangible Assets | 11.7M | 10.4M | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 77.8M | 53.9M | 216.6M | 128.2M | 21.0M |
| Total Non-Current Assets | 2.9B | 2.4B | 1.7B | 823.2M | 506.3M |
| Total Assets | 6.5B | 5.0B | 3.5B | 2.3B | 2.0B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 741.6M | 600.3M | 513.4M | 237.6M | 261.7M |
| Short-term Debt | 1.0B | 844.2M | 388.2M | 52.6M | 36.5M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 662.0K | 217.9M | 109.1M | 43.3M | 33.7M |
| Total Current Liabilities | 2.2B | 1.9B | 1.2B | 415.3M | 436.3M |
| Non-Current Liabilities | |||||
| Long-term Debt | 758.7M | 731.6M | 109.2M | 124.9M | 85.9M |
| Deferred Tax Liabilities | 424.0K | 0 | 4.0M | 9.6M | 19.7M |
| Other Non-Current Liabilities | 59.9M | -1.0K | -2.0K | 2.0K | -1.0K |
| Total Non-Current Liabilities | 902.3M | 752.7M | 126.5M | 143.8M | 112.1M |
| Total Liabilities | 3.1B | 2.7B | 1.3B | 559.1M | 548.3M |
| Equity | |||||
| Common Stock | 68.9M | 58.2M | 57.7M | 57.7M | 57.3M |
| Retained Earnings | 1.7B | 1.9B | 1.7B | 1.6B | 1.4B |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 3.4B | 2.4B | 2.2B | 1.7B | 1.4B |
| Key Metrics | |||||
| Total Debt | 1.8B | 1.6B | 497.4M | 177.5M | 122.4M |
| Working Capital | 1.4B | 695.3M | 644.9M | 1.0B | 1.0B |
Balance Sheet Composition
Bharat Parenterals Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -339.5M | 187.2M | 235.5M | 278.8M | 271.2M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | 0 | 1.4M | 5.3M | -4.0M | 0 |
| Working Capital Changes | -406.7M | -394.2M | -369.9M | -259.4M | 97.7M |
| Operating Cash Flow | -654.3M | -175.9M | -110.6M | 8.3M | 369.2M |
| Investing Activities | |||||
| Capital Expenditures | -286.2M | -1.0B | -900.9M | -388.7M | -7.8M |
| Acquisitions | -543.9M | - | - | - | - |
| Investment Purchases | -52.7M | - | - | - | - |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | -1.4B | -1.0B | -909.4M | -394.0M | -7.7M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | -5.8M | -4.3M | - | - | - |
| Debt Issuance | 27.0M | 622.4M | 0 | 39.2M | 112.0M |
| Debt Repayment | - | - | -12.4M | - | -14.5M |
| Financing Cash Flow | 1.7B | 1.1B | 627.9M | 103.2M | 108.9M |
| Free Cash Flow | -563.3M | -1.1B | -699.4M | -399.4M | 236.1M |
| Net Change in Cash | -356.0M | -88.0M | -392.1M | -282.5M | 470.5M |
Cash Flow Trend
Bharat Parenterals Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-18.20
Price to Book
1.90
Price to Sales
2.39
PEG Ratio
-0.45
Profitability Ratios
Profit Margin
-2.32%
Operating Margin
-10.30%
Return on Equity
-3.72%
Return on Assets
-1.95%
Financial Health
Current Ratio
2.17
Debt to Equity
39.74
Beta
0.57
Per Share Data
EPS (TTM)
₹-42.80
Book Value per Share
₹640.06
Revenue per Share
₹553.27
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| BPLPHARMA | 8.4B | -18.20 | 1.90 | -3.72% | -2.32% | 39.74 |
| Sun Pharmaceutical | 3.9T | 36.73 | 5.15 | 15.08% | 19.21% | 6.68 |
| Divi's Laboratories | 1.7T | 67.11 | 10.82 | 14.64% | 24.04% | 0.58 |
| Sun Pharma Advanced | 46.7B | -13.65 | -13.55 | 157.88% | -53.22% | -1.21 |
| Innova Captab | 41.4B | 31.20 | 4.05 | 13.37% | 8.85% | 32.95 |
| Gujarat Themis | 35.4B | 73.73 | 13.36 | 19.64% | 29.99% | 27.04 |
Financial data is updated regularly. All figures are in the company's reporting currency.





